Healthcare May 13, 2021 12:27 PM (GMT+8) · EqualOcean
"Kewang medicine" has recently completed 105 million US dollars in round C financing. This round of financing is led by the joint homeland development fund of Dawan District, with the joint participation of cormorant asset management, maixing investment and superstring capital. Existing investors Lilly Asia Fund, highland capital, CDH investment, Deyi capital and Yuanhe holdings continue to increase their holdings. The funds raised will be used to expand the strategic layout of Kewang pharmaceutical in global R & D. In addition, the company will use funds to explore new immunotherapy mechanisms and expand global cooperation.